Correction

04/22/2013

A summary in the April 12 edition of DiabetesPro SmartBrief gave the incorrect name of the drug that showed the lowest risk of new-onset diabetes for participants in a meta-analysis. The name of the drug is pravastatin. SmartBrief regrets the error.

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Senior Legal Counsel
Alcon
Fort Worth, TX
Senior Scientist - Cell Engineering Group
Pfizer
San Francisco, CA
Associate Director, Compliance Business Partner I
Boehringer Ingelheim
Ridgefield, CT
Attorney
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC